Clinical trial to determine effects of cetuximab on high risk oral premalignancy.
Patients with mild, moderate, severe head and neck dysplasia enrolled.
Primary objective to determine histologic response to treatment with cetuximab.
Cetuximab may result in histological resolution in at least a subset of patients.